Prevalence of Human Immunodeficiency Virus among Presumptive Tuberculosis Patients Offered HIV Testing Services in Federal Capital Territory, Abuja Nigeria
Virus has a prevalence of 1.4% in Nigeria, 2.0% in North Central Nigeria and, 1.4%
among adults in Abuja. This study determined prevalence and predictors of Human
Immunodeficiency Virus among 737 presumptive tuberculosis patients in Federal Capital
Territory Abuja Nigeria from 1st April 2019 to 30th May 2021
through retrospective cross-sectional study and multi-stage sampling.
From Non-Municipal Area Councils, Bwari
was selected while from Health Facilities, General Hospital Bwari and Gwarimpa were
selected from Bwari and Abuja Municipal Area Council respectively by simple random
sampling and data abstractions
were done and analyzed using
Statistical Package for Social Sciences version 23.0 Software. The prevalence of
Human Immunodeficiency Virus amongst patients with known status was 29.0%, unknown
status 1.9% while their cumulative prevalence was 30.7%. The prevalence of Human
Immweredeficiency Virus amongst patients with tuberculosis was 1.1%. Factors associated
with Human Immunodeficiency Virus were Area Council (p = 0.001), age (p = 0.001)
and gender (p = 0.001). For predictors, residency in Bwari was 0.196 times less
likely compared to residency at AMAC, Abuja and, place of Residence was a predictor
(aOR = 0.001; 95% C.I. = 0.130-295). The age group 31-40 years were 2 times more
likely compared to other age groups and, age it was predictor (aOR = 0.019; 95%
C.I. = 1.125-3.852). and male gender gender were 0.601 time less likely compared
to females and, gender is a predictor (aOR = 0.021; 95% C.I. = 0.391-0.925).
AIDS Control Agency. (2020). About HIV/AIDS - NACA Nigeria. Retrieved April
11, 2021, from https://naca.gov.ng/about-hivaids/.
Health Organization. (n.d.). HIV/AIDS. Retrieved April 11, 2021, from https://naca.gov.ng/about-hiv-aids/.
Health Organization. (2018). HIV/AIDS | WHO | Regional Office for Africa.
Retrieved April 11, 2021, from https://www.afro.who.int/health-topics/hivaids.
Health Organization. (n.d.). HIV/AIDS. Retrieved April 11, 2021, from https://www.who.int/health-topics/hiv-aids#tab=tab_1.
UNAIDS. (2020). Global HIV & AIDS statistics — 2020 fact sheet | UNAIDS.
Retrieved April 12, 2021, from https://www.unaids.org/en/resources/fact-sheet.
Labour Organization. (n.d.). HIV/AIDS in Africa (Africa). Retrieved April 11,
2021, from https://www.ilo.org/africa/areas-of-work/hiv-aids/lang--en/index.htm.
I., Schaffnit, S. B., Kwaro, D., Shahmanesh, M., Ziraba, A., Kabiru, C. W., Phillips-Howard,
P., Chimbindi, N., Ondeng’E, K., Gourlay, A., Cowan, F. M., Hargreaves, J. R., Hensen,
B., Chiyaka, T., Glynn, J. R., & Floyd, S. (2018). Evaluating the impact of
the DREAMS partnership to reduce HIV incidence among adolescent girls and young
women in four settings: A study protocol. BMC Public Health, 18(1).
for Disease Control and Prevention. (2020). Global Health - Newsroom - Tuberculosis.
Retrieved April 10, 2021, from https://www.cdc.gov/globalhealth/newsroom/topics/tb/index.html.
(2019). New survey results indicate that Nigeria has an HIV prevalence of 1.4%
| UNAIDS. Retrieved April 11, 2021, from https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190314_nigeria.
NAIIS. (2019). Key findings. Retrieved April 12, 2021, from https://naiis.ng/resource/factsheet/NAIIS National Summary Sheet.pdf.
NACA. (2019). Nigeria prevalence rate - NACA Nigeria. Retrieved April
12, 2021, from https://naca.gov.ng/nigeria-prevalence-rate/.
A. L., Schomaker, M., Davies, M. A., Williams, P., Balkan, S., Ben-Farhat, J., Calles,
N., Chokephaibulkit, K., Duff, C., Eboua, T. F., Kekitiinwa-Rukyalekere, A., Maxwell,
N., Pinto, J., Seage, G., Teasdale, C. A., Wanless, S., Warszawski, J., Wools-Kaloustian,
K., Yotebieng, M.,Leroy, V. (2018). The epidemiology of adolescents living with
perinatally acquired HIV: A cross-region global cohort analysis. Plos Medicine,
World Health Organization. (2020). Tuberculosis. Retrieved March 30,
2021, from https://www.who.int/news-room/fact-sheets/detail/tuberculosis.
World Health Organization. (n.d.). Tuberculosis (TB) | WHO | Regional Office
for Africa Organization. Retrieved April 11, 2021, from https://www.afro.who.int/health-topics/tuberculosis-tb.
Health Organization. (n.d.). Tuberculosis (TB) | WHO | Regional Office for Africa
Organization. Retrieved April 11, 2021, from https://www.afro.who.int/health-topics/tuberculosis-tb.
Ministry of Health Nigeria. (2010). National Tuberculosis and Leprosy Control
Programme: Workers’ manual – Revise 5th Edition 1. Retrieved April 2, 2021,
Hassan, A., Olukolade, R., Ogbuji, Q., Onyemocho, A., Okwuonye, L., Igbabul,
S., Okechukwu, J., Kusimo, O., Osho, A., Osinowo, K., & Ladipo, O. (2016). Evaluation
of Tuberculosis Treatment Outcome of TB/HIV Co-Infection: A Four-Year Retrospective
Cohort Study in HIV-Prevalent Setting of North Central Nigeria. Journal of Tuberculosis
Research, 04(03), 122–133. https://doi.org/10.4236/jtr.2016.43015.
C., Harries, A. D., Maher, D., Hosseini, S. M., Nkhoma, W., & Salaniponi, F.
M. (2006). Tuberculosis. In Disease and Mortality in Sub-Saharan Africa.
The International Bank for Reconstruction and Development / The World Bank. http://www.ncbi.nlm.nih.gov/pubmed/21290646.
U. U., Dahiru, T., Olorukooba, A., Daam, C. K., Waziri, H. S., Adebowale, A.,
Waziri, N. E., & Nguku, P. (2020). Determinants of perinatal mortality in
public secondary health facilities, Abuja municipal area council, Federal
Capital Territory, Abuja, Nigeria. Pan African Medical Journal, 37(114), 1–12. https://doi.org/10.11604/pamj.2020.37.114.17108.
Capital Territory. (2019). Federal Capital Territory (FCT) Health Sector
Resource Mobilisation Plan (2018–2022). http://www.healthpolicyplus.com/ns/pubs/17373-17676_NigeriaFCTRMP.pdf.
Hamisu, A. W., Etapelong, S. G., Ayodeji, I. H., Furera, Z., Ningi, N.,
Jimoh, A., Fiona, B., Banda, R., Tegegne, S. G., Ajogwu, A., Nwachukwu, J.,
John, D., Abdurrahman, S., Ahmed, F., Adesola, L., Teresa, N., Adesola, O.,
Rahmat, A., Elizabeth, A., & Lydia, T. (2020). Assessment of the
contribution of community active surveillance to covid-19 case detection in the
Federal Capital Territory, Abuja, Nigeria. African Journal of Biology and
Medical Research, 3(2), 98–110. www.abjournals.org.
Kamweli, M., Id, A., Kwaga, J., Okolocha, E., & Mba, N. (2019).
Prevalence and risk factors for multi-drug resistant Escherichia coli among
poultry workers in the Federal Capital Territory , Abuja , Nigeria Prevalence
and risk factors for multi-drug resistant Escherichia coli among poultry
workers in the Federal Capit. November. https://doi.org/10.1371/journal.pone.0225379.
K. W. Y., Kyaw, N. T. T., Kyi, M. S., Aye, S., Harries, A. D., Kumar, A. M. V.,
Oo, N. L., Satyanarayana, S., & Aung, S. T. (2020). HIV testing uptake and HIV
positivity among presumptive tuberculosis patients in Mandalay, Myanmar, 2014-2017.
Plos One, 15(6), e0234429. https://doi.org/10.1371/journal.pone.0234429.
A. M., Gupta, D., Kumar, A., Gupta, R. S., Kanchar, A., Rao, R., Shastri, S., Suryakanth,
M. D., Rangaraju, C., Naik, B., Guddemane, D. K., Bhat, P., Nair, A. S., Harries,
A. D., & Dewan, P. (2016). HIV testing among patients with presumptive tuberculosis:
How do we implement it in a routine programmatic setting? Results of a large operational
research from India. PLoS ONE, 11(5), e0156487. https://doi.org/10.1371/journal.pone.0156487.
R. A., Hwalima, Z. E., Sithole, S., Takarinda, K. C., Tayler-Smith, K., &
Harries, A. D. (2015). Are HIV-positive presumptive tuberculosis patients
without tuberculosis getting the care they need in Zimbabwe? Public Health
Action, 5(4), 217–221. https://doi.org/10.5588/pha.15.0036.
A. G., Dejene, T. A., & Hailu, G. G. (2020). Frequency of MTB and
rifampicin resistance MTB using Xpert-MTB/RIF assay among adult presumptive
tuberculosis patients in Tigray, Northern Ethiopia: A cross sectional study.
PLoS ONE, 15(11 November), e0240361. https://doi.org/10.1371/journal.pone.0240361.
P., Lebina, L., Motsomi, K., Bosch, Z., Milovanovic, M., Ratsela, A., Lala, S.,
Variava, E., Golub, J. E., Webb, E. L., & Martinson, N. A. (2020). Prevalence
and risk factors for latent tuberculosis infection among household contacts of index
cases in two South African provinces: Analysis of baseline data from a cluster-randomised
trial. PLOS ONE, 15(3), e0230376. https://doi.org/10.1371/Journal.Pone.0230376.
B., Tigabu, A., Tadesse, T., Tegegne, Z., Hailu, W., Mahmud, E., Sisay, T., &
Sendeku, W. (2021). Mycobacterium tuberculosis and HIV co-infection among presumptive
tuberculosis cases and asthmatic patients at university of gondar hospital, northwest
ethiopia. Clinical Laboratory, 67(1), 1–8. https://doi.org/10.7754/Clin.Lab.2020.200458.
(2020). About HIV/AIDS - NACA Nigeria. Retrieved April 11, 2021, from https://naca.gov.ng/about-hivaids/.
I. O., Ejike, I. U., Innocent-Adiele, C., & Cookey, T. I. (2020). HIV coinfections
with tuberculosis among HIV-1 infected individuals in old cross river state, Nigeria.
Journal of Immunoassay and Immunochemistry, 41(3), 245–256. https://doi.org/10.1080/15321819.2020.1717527.
M. A., Abdulkadir, B., Y. Y. Riko, Farida, A. T., Mujahid, H., Ezekiel, B. K., Usman,
A., Ahmad, M. A., Isah, M. G. and Murtala, S. (2020). A Survey on Tuberculosis and
HIV Co-Infection among Presumptive Tuberculosis Patients within Zuru Emirate Council,
Kebbi State, Nigeria. Nigerian Journal of Microbiology, 34(2), 5380–5389.
J.J., Duah, H.O., Agbadi, P. et al. (2020). Spatial analysis of factors associated
with HIV infection in Malawi: indicators for effective prevention. BMC Public
Health 20, 1167. https://doi.org/10.1186/s12889-020-09278-0.
JdD, Gabriel EL, Kengne Nde C, Fokam J, Tseuko DG, Messeh A, et al. (2019) Factors
associated with risk of HIV-infection among pregnant women in Cameroon: Evidence
from the 2016 national sentinel surveillance survey of HIV and syphilis. Plos
One 14(4): e0208963. https://doi.org/10.1371/journal.pone.0208963.